Rosen Law Firm Urges DermTech, Inc. Investors to Act Before the December 15 Deadline

Investors of DermTech, Inc. DMTK, a notable company specializing in non-invasive genomic tests for skin cancer and other diseases, are facing an important deadline. The Rosen Law Firm, a distinguished global investor rights law firm, has issued a reminder to those who purchased DMTK securities between May 3, 2022, and November 3, 2022, about the approaching December 15, 2023 cutoff. This date is crucial for investors with losses exceeding $100,000 to seek counsel and potentially join a securities class action lawsuit.

Understanding the Lawsuit

The class action against DermTech alleges that the company may have provided misleading information to the public, possibly violating federal securities laws. The lawsuit is focused on whether DermTech failed to disclose pertinent details that could affect the value of its securities, leading to financial losses for investors. As the December 15 deadline draws near, investors are encouraged to contact legal counsel to assert their rights.

About DermTech, Inc.

Headquartered in La Jolla, California, DermTech Inc. DMTK is pioneering the field of molecular diagnostics. Their innovative approach permits non-invasive screening methods aimed at the early detection of skin cancers, inflammatory diseases, and various age-related conditions. This groundbreaking technology has the potential to revolutionize dermatological diagnosis and offers a promising future for the company and its stakeholders.

Investor Action Encouraged

With the deadline imminent, it's critical for investors who have encountered substantial losses to deliberate on their choices. The Rosen Law Firm is actively reaching out to investors to ensure they are aware of their rights and the potential for recovery through legal action. Investors in DMTK who have witnessed significant financial downturns during the specified period should consider seeking legal advice without delay.

Rosen, DMTK, Deadline